These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 31012549)
1. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts. Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549 [TBL] [Abstract][Full Text] [Related]
2. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279 [TBL] [Abstract][Full Text] [Related]
3. An Fc-engineered CD19 antibody eradicates MRD in patient-derived Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469 [TBL] [Abstract][Full Text] [Related]
5. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381 [TBL] [Abstract][Full Text] [Related]
6. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group. Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894 [TBL] [Abstract][Full Text] [Related]
7. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015 [TBL] [Abstract][Full Text] [Related]
12. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia. Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559 [TBL] [Abstract][Full Text] [Related]
13. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts. Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091 [TBL] [Abstract][Full Text] [Related]
14. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Schwemmlein M; Stieglmaier J; Kellner C; Peipp M; Saul D; Oduncu F; Emmerich B; Stockmeyer B; Lang P; Beck JD; Fey GH Leukemia; 2007 Jul; 21(7):1405-12. PubMed ID: 17495978 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Ryan MC; Palanca-Wessels MC; Schimpf B; Gordon KA; Kostner H; Meyer B; Yu C; Van Epps HA; Benjamin D Blood; 2017 Nov; 130(18):2018-2026. PubMed ID: 28903943 [TBL] [Abstract][Full Text] [Related]
16. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; Rossi D; Stussi G; Zucca E; Stathis A; Sloss CM; Bertoni F Haematologica; 2019 Aug; 104(8):1633-1639. PubMed ID: 30733273 [TBL] [Abstract][Full Text] [Related]
17. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707 [TBL] [Abstract][Full Text] [Related]
18. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA MAbs; 2015; 7(3):584-604. PubMed ID: 25875246 [TBL] [Abstract][Full Text] [Related]
19. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Farhadfar N; Litzow MR Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873 [TBL] [Abstract][Full Text] [Related]
20. Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia. Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB Br J Cancer; 2020 Sep; 123(5):742-751. PubMed ID: 32536690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]